Oxurion NV is a biopharmaceutical company headquartered in Leuven, Belgium, specializing in the development of next-generation therapies to preserve vision and prevent blindness in patients with retinal disorders. Founded in 1991 and formerly known as ThromboGenics NV until its rebranding in September 2018, the company targets conditions such as Geographic Atrophy and Age-related Macular Degeneration, the leading cause of vision loss among the elderly worldwide. Key pipeline candidates include THR-149, a plasma kallikrein inhibitor aimed at patients sub-optimally responding to anti-VEGF therapies, and THR-687, a pan-RGD integrin inhibitor designed as a potential standard of care for broader AMD populations. Oxurion employs innovative approaches like CRISPR-based target discovery to identify cytoprotective targets, addressing unmet needs in ophthalmology. With a lean team of about 11 employees, leadership includes CEO and CFO Pascal Ghoson, alongside executives like Andy De Deene and Philippe Barbeaux, and a board featuring Independent Chairman Charles Paris de Bollardiere. Recently, Oxurion has also pursued strategic acquisitions, such as a majority stake in Axiodis CRO, to build capabilities in biometrics and support healthcare stakeholders. In the financial markets, Oxurion NV represents a focused player in biotechnology, contributing to advancements in retinal disease treatments.